Using Pharmacogene polymorphism panels to detect Germline Pharmacodynamic markers in oncology

Clinical Cancer Research

Volumn 20, Issue 10, 2014, Pages 2530-2540

  Hertz, Daniel L ^a   McLeod, Howard L ^b,c  

^a UNIVERSITY OF MICHIGAN   (United States)

^b H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^c DeBartolo Family Personalized Medicine Institute   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE; BORTEZOMIB; BUSULFAN; CISPLATIN; CYCLOPHOSPHAMIDE; CYTARABINE; DOCETAXEL; DOXORUBICIN; FLUDARABINE; FLUOROURACIL; GEMTUZUMAB OZOGAMICIN; IDARUBICIN; IRINOTECAN; METHOTREXATE; PACLITAXEL; THALIDOMIDE; VINCRISTINE; ZOLEDRONIC ACID; ANTINEOPLASTIC AGENT; TUMOR MARKER;

ABCB1 GENE; ABCG1 GENE; ALDH1A GENE; AREA UNDER THE CURVE; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CARDIOTOXICITY; CASTRATION RESISTANT PROSTATE CANCER; CHILDHOOD CANCER; CHST1 GENE; CYP39A1 GENE; DRUG CLEARANCE; DRUG METABOLISM; DRUG TRANSPORT; GASTROINTESTINAL TOXICITY; GENE; GENETIC ASSOCIATION; GENETIC MARKER; GENOTYPING TECHNIQUE; HUMAN; INFUSION RELATED REACTION; JAW OSTEONECROSIS; LIVER TOXICITY; MYELOMA; NEUROPATHY; NEUTROPENIA; ONCOLOGY; OSTEOSARCOMA; OTOTOXICITY; OVERALL SURVIVAL; PHARMACODYNAMICS; PHARMACOGENETICS; PHENOTYPE; PRIORITY JOURNAL; SINGLE NUCLEOTIDE POLYMORPHISM; SLC22A12 GENE; SLCO1B1 GENE; SULT2B1 GENE; TREATMENT OUTCOME; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT; VENOUS THROMBOEMBOLISM; BIOLOGICAL MODEL; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; GENETICS; METABOLISM; NEOPLASMS; PROCEDURES;

ANTINEOPLASTIC AGENTS; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; HUMANS; MODELS, GENETIC; NEOPLASMS; PHARMACOGENETICS; POLYMORPHISM, SINGLE NUCLEOTIDE; TUMOR MARKERS, BIOLOGICAL;

EID: 84901036161     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-13-2780     Document Type: Article

References (63)

1. McLeod HL. Cancer pharmacogenomics: early promise, but concerted effort needed. Science 2013;339:1563-6.
2. Hertz DL, McLeod HL. Use of pharmacogenetics for predicting cancer prognosis and treatment exposure, response and toxicity. J Hum Genet 2013;58:346-52.
3. Collins FS, Barker AD. Mapping the cancer genome. pinpointing the genes involved in cancer will help chart a new course across the complex landscape of human malignancies. Sci Am 2007; 296:50-7.
4. Roychowdhury S, Iyer MK, Robinson DR, Lonigro RJ, Wu YM, Cao X, et al. Personalized oncology through integrative high-throughput sequencing: a pilot study. Sci Transl Med 2011;3:111ra121.
5. Evans WE, Relling MV. Pharmacogenomics: translating functional genomics into rational therapeutics. Science 1999;286:487-91.
6. Relling MV, Gardner EE, Sandborn WJ, Schmiegelow K, Pui CH, Yee SW, et al. Clinical pharmacogenetics implementation consortium guidelines for thiopurine methyltransferase genotype and thiopurine dosing: 2013 update. Clin Pharmacol Ther 2013;93:324-5.
7. Tutt A, Robson M, Garber JE, Domchek SM, Audeh MW, Weitzel JN, et al. Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial. Lancet 2010;376:235-44.
8. Leandro-Garcia LJ, Leskela S, Jara Sanchez C, Green H, Avall Lundqvist E, Wheeler HE, et al. Regulatory polymorphisms in b-tubulin IIa are associated with paclitaxel-induced peripheral neuropathy. Clin Cancer Res 2012;18:4441-8.
9. Abraham JE, Guo Q, Dorling L, Tyrer J, Ingle S, Hardy R, et al. Replication of genetic polymorphisms reported to be associated with taxane-related sensory neuropathy in early breast cancer patients treated with paclitaxel. Clin Cancer Res 2014 Mar 05 [Epub ahead of print].
10. Ioannidis JP, Tarone R, McLaughlin JK. The false-positive to falsenegative ratio in epidemiologic studies. Epidemiology 2011;22:450-6.
11. Low S-K, Takahashi A, Mushiroda T, Kubo M. Genome-wide association study: a useful tool to identify common genetic variants associated with drug toxicity and efficacy in cancer pharmacogenomics. Clin Cancer Res 2014;20:2541-52.
12. Feng J, Sun J, Wang MZ, Zhang Z, Kim S, Zhu Y, et al. Compilation of a comprehensive gene panel for systematic assessment of genes thatgovern an individual's drug responses. Pharmacogenomics 2010;11: 1403-25.
13. Gainor JF, Longo DL, Chabner BA. Pharmacodynamic biomarkers: falling short of the mark? Clin Cancer Res 2014;20:2587-94.
14. Wheeler HE, Gamazon ER, Wing C, Njiaju UO, Njoku C, Baldwin RM, et al. Integration of cell line and clinical trial genomewide analyses supports a polygenic architecture of paclitaxelinduced sensory peripheral neuropathy. Clin Cancer Res 2013; 19:491-9.
15. Sato Y, Yamamoto N, Kunitoh H, Ohe Y, Minami H, Laird NM, et al. Genome-wide association study on overall survival of advanced nonsmall cell lung cancer patients treated with carboplatin and paclitaxel. J Thorac Oncol 2011;6:132-8.
16. Ross JS, Ali SM, Wang K, Palmer G, Yelensky R, Lipson D, et al. Comprehensive genomic profiling of epithelial ovarian cancer by next generation sequencing-based diagnostic assay reveals new routes to targeted therapies. Gynecol Oncol 2013;130: 554-9.
17. Fernandez CA, Smith C, Yang W, Lorier R, Crews KR, Kornegay N, et al. Concordance of DMET plus genotyping results with those of orthogonal genotyping methods. Clin Pharmacol Ther 2012;92: 360-5.
18. He YJ, Misher AD, Irvin W Jr., Motsinger-Reif A, McLeod HL, Hoskins JM. Assessing the utility of whole genome amplifiedDNA as a template for DMET plus array. Clin Chem Lab Med 2012;50:1329-34.
19. Hu Y, Ehli EA, Nelson K, Bohlen K, Lynch C, Huizenga P, et al. Genotyping performance between saliva and blood-derived genomic DNAs on the DMET array: a comparison. PLoS ONE 2012;7: e33968.
20. Guzzi PH, Agapito G, Di Martino MT, Arbitrio M, Tassone P, Tagliaferri P, et al. DMET-Analyzer: automatic analysis of affymetrix DMET data. BMC Bioinformat 2012;13:258.
21. Weissensteiner H, Haun M, Schonherr S, Neuner M, Forer L, Specht G, et al. SNPflow: a lightweight application for the processing, storing and automatic quality checking of genotyping assays. PLoS ONE 2013;8: e59508.
22. ten Brink MH, Swen JJ, Bohringer S, Wessels JA, van der Straaten T, Marijt EW, et al. Exploratory analysis of 1936 SNPs in ADME genes for association with busulfan clearance in adult hematopoietic stem cell recipients. Pharmacogenet Genomics 2013;23:675-83.
23. ten Brink MH, Wessels JA, den Hartigh J, van der Straaten T, von dem Borne PA, Guchelaar HJ, et al. Effect of genetic polymorphisms in genes encoding GST isoenzymes on BU pharmacokinetics in adult patients undergoing hematopoietic SCT. Bone Marrow Transplant 2012;47:190-5.
24. Kusama M, Kubota T, Matsukura Y, Matsuno K, Ogawa S, Kanda Y, et al. Influence of glutathione S-transferase A1 polymorphism on the pharmacokinetics of busulfan. Clin Chim Acta 2006;368: 93-8.
25. de Graan AJ, Elens L, Smid M, Martens JW, Sparreboom A, Nieuweboer AJ, et al. A pharmacogenetic predictive model for paclitaxel clearance based on the DMET platform. Clin Cancer Res 2013;19: 5210-7.
26. Bergmann TK, Brasch-Andersen C, Green H, Mirza M, Pedersen RS, Nielsen F, et al. Impact of CYP2C83 on paclitaxel clearance: a population pharmacokinetic and pharmacogenomic study in 93 patients with ovarian cancer. Pharmacogenomics J 2011;11: 113-20.
27. Saito Y, Katori N, Soyama A, Nakajima Y, Yoshitani T, Kim SR, et al. CYP2C8 haplotype structures and their influence on pharmacokinetics of paclitaxel in a Japanese population. Pharmacogenet Genomics 2007;17:461-71.
28. Smith NF, Marsh S, Scott-Horton TJ, Hamada A, Mielke S, Mross K, et al. Variants in the SLCO1B3 gene: interethnic distribution and association with paclitaxel pharmacokinetics. Clin Pharmacol Ther 2007;81:76-82.
29. Nakajima M, Fujiki Y, Kyo S, Kanaya T, Nakamura M, Maida Y, et al. Pharmacokinetics of paclitaxel in ovarian cancer patients and genetic polymorphisms of CYP2C8, CYP3A4, and MDR1. J Clin Pharmacol 2005;45:674-82.
30. Fransson MN, Green H, Litton J, Friberg LE. Influence of cremophor EL and genetic polymorphisms on the pharmacokinetics of paclitaxel and its metabolites using a mechanism-based model. Drug Metab Dispos 2011;39:247-55.
31. Uchiyama T, Kanno H, Ishitani K, Fujii H, Ohta H, Matsui H, et al. An SNP in CYP39A1 is associated with severe neutropenia induced by docetaxel. Cancer Chemother Pharmacol 2012; 69:1617-24.
32. Sissung TM, Baum CE, Deeken J, Price DK, Aragon-Ching J, Steinberg SM, et al. ABCB1 genetic variation influences the toxicity and clinical outcome of patients with androgen-independent prostate cancer treated with docetaxel. Clin Cancer Res 2008;14: 4543-9.
33. de Graan AM, Lancaster CS, Obaidat A, Hagenbuch B, Elens L, Friberg LE, et al. Influence of polymorphic OATP1B-type carriers on the disposition of docetaxel. Clin Cancer Res 2012;18: 4433-40.
34. Deeken JF, Cormier T, Price DK, Sissung TM, Steinberg SM, Tran K, et al. A pharmacogenetic study of docetaxel and thalidomide in patients with castration-resistant prostate cancer using the DMET genotyping platform. Pharmacogenomics J 2010;10:191-9.
35. Iacobucci I, Lonetti A, Candoni A, Sazzini M, Papayannidis C, Formica S, et al. Profiling of drug-metabolizing enzymes/transporters in CD33 acute myeloid leukemia patients treated with gemtuzumab-ozogamicin and fludarabine, cytarabine and idarubicin. Pharmacogenomics J 2013;13:335-41.
36. Rumiato E, Boldrin E, Amadori A, Saggioro D. DMET (drug-metabolizing enzymes and transporters) microarray analysis of colorectal cancer patients with severe 5-fluorouracil-induced toxicity. Cancer Chemother Pharmacol 2013;72:483-8.
37. Di Martino MT, Arbitrio M, Leone E, Guzzi PH, Saveria Rotundo M, Ciliberto D, et al. Single nucleotide polymorphisms of ABCC5 and ABCG1 transporter genes correlate to irinotecan-Associated gastrointestinal toxicity in colorectal cancer patients: a DMET microarray profiling study. Cancer Biol Ther 2011;12:780-7.
38. Innocenti F, Kroetz DL, Schuetz E, Dolan ME, Ramirez J, Relling M, et al. Comprehensive pharmacogenetic analysis of irinotecan neutropenia and pharmacokinetics. J Clin Oncol 2009;27: 2604-14.
39. Han JY, Lim HS, Shin ES, Yoo YK, Park YH, Lee JE, et al. Influence of the organic anion-transporting polypeptide 1B1 (OATP1B1) polymorphisms on irinotecan-pharmacokinetics and clinical outcome of patients with advanced non-small cell lung cancer. Lung Cancer 2008;59:69-75.
40. Di Martino MT, Arbitrio M, Guzzi PH, Leone E, Baudi F, Piro E, et al. A peroxisome proliferator-Activated receptor gamma (PPARG) polymorphism is associated with zoledronic acid-related osteonecrosis of the jaw in multiple myeloma patients: analysis by DMET microarray profiling. Br J Haematol 2011;154:529-33.
41. Sarasquete ME, Garcia-Sanz R, Marin L, Alcoceba M, Chillon MC, Balanzategui A, et al. Bisphosphonate-related osteonecrosis of the jaw is associated with polymorphisms of the cytochrome P450 CYP2C8 in multiple myeloma: a genome-wide single nucleotide polymorphism analysis. Blood 2008;112:2709-12.
42. Hertz DL, Dees EC, Motsinger-Reif AA, Drobish A, Roy S, McLeod HL, et al. Interrogation of polymorphisms in drug metabolism or transport genes and peripheral neuropathy during paclitaxel treatment [abstract]. ASCO Meeting Abstr 2012;30 Suppl 15:10515.
43. Lin CH, Yeakley JM, McDaniel TK, Shen R. Medium-to high-throughput SNP genotyping using VeraCode microbeads. Methods Mol Biol 2009;496:129-42.
44. Ross CJ, Katzov-Eckert H, Dube MP, Brooks B, Rassekh SR, Barhdadi A, et al. Genetic variants in TPMT and COMT are associated with hearing loss in children receiving cisplatin chemotherapy. Nat Genet 2009;41:1345-9.
45. Pussegoda K, Ross CJ, Visscher H, Yazdanpanah M, Brooks B, Rassekh SR, et al. Replication of TPMT and ABCC3 genetic variants highly associated with cisplatin-induced hearing loss in children. Clin Pharmacol Ther 2013;94:243-51.
46. Yang JJ, Lim JY, Huang J, Bass J, Wu J, Wang C, et al. The role of inherited TPMT and COMT genetic variation in cisplatin-induced ototoxicity in children with cancer. Clin Pharmacol Ther 2013;94: 252-9.
47. Carleton BC, Ross CJ, Bhavsar AP, Amstutz U, Pussegoda K, Visscher H, et al. Role of TPMT and COMT genetic variation in cisplatin-induced ototoxicity. Clin Pharmacol Ther 2014;95:253.
48. Ratain MJ, Cox NJ, Henderson TO. Challenges in interpreting the evidence for genetic predictors of ototoxicity. Clin Pharmacol Ther 2013;94:631-5.
49. Hertz DL, McLeod HL, Irvin WJ. Tamoxifen and CYP2D6: a contradiction of data. Oncologist 2012;17:620-30.
50. Kiyotani K, Mushiroda T, Hosono N, Tsunoda T, Kubo M, Aki F, et al. Lessons for pharmacogenomics studies: association study between CYP2D6 genotype and tamoxifen response. Pharmacogenet Genomics 2010;20:565-8.
51. Province MA, Goetz MP, Brauch H, Flockhart DA, Hebert JM, Whaley R, et al. CYP2D6 genotype and adjuvant tamoxifen: meta-Analysis of heterogeneous study populations. Clin Pharmacol Ther 2014;95: 216-27.
52. Visscher H, Ross CJ, Rassekh SR, Barhdadi A, Dube MP, Al-Saloos H, et al. Pharmacogenomic prediction of anthracycline-induced cardiotoxicity in children. J Clin Oncol 2012;30:1422-8.
53. Visscher H, Ross CJ, Rassekh SR, Sandor GS, Caron HN, van Dalen EC, et al. Validation of variants in SLC28A3 and UGT1A6 as genetic markers predictive of anthracycline-induced cardiotoxicity in children. Pediatr Blood Cancer 2013;60:1375-81.
54. Kim KI, Huh I, Kim I, Park T, Ahn K, Yoon S, et al. Combined interaction of multi-locus genetic polymorphisms in cytarabine arabinoside metabolic pathway on clinical outcomes in adult acute myeloid leukaemia (AML) patients. Eur J Cancer 2013;49:403-10.
55. Xu PP, Chen BA, Feng JF, Cheng L, Xia GH, Li YF, et al. Association of polymorphisms of cytosine arabinoside-metabolizing enzyme gene with therapeutic efficacy for acute myeloid leukemia. Chin Med J (Engl) 2012;125:2137-43.
56. Caronia D, Patino-Garcia A, Perez-Martinez A, Pita G, Moreno LT, Zalacain-Diez M, et al. Effect of ABCB1 and ABCC3 polymorphisms on osteosarcoma survival after chemotherapy: a pharmacogenetic study. PLoS ONE 2011;6:e26091.
57. Van Ness B, Ramos C, Haznadar M, Hoering A, Haessler J, Crowley J, et al. Genomic variation in myeloma: design, content, and initial application of the Bank On A Cure SNP panel to detect associations with progression-free survival. BMC Med 2008;6:26.
58. Johnson DC, Corthals S, Ramos C, Hoering A, Cocks K, Dickens NJ, et al. Genetic associations with thalidomide mediated venous thrombotic events in myeloma identified using targeted genotyping. Blood 2008;112:4924-34.
59. Almasi M, Sevcikova S, Slaby O, Kaisarova P, Maisnar V, Penka M, et al. Association study of selected genetic polymorphisms and occurrence of venous thromboembolism in patients with multiple myeloma who were treated with thalidomide. Clin Lymphoma Myeloma Leuk 2011;11:414-20.
60. Corthals SL, Kuiper R, Johnson DC, Sonneveld P, Hajek R, van der Holt B, et al. Genetic factors underlying the risk of bortezomib induced peripheral neuropathy in multiple myeloma patients. Haematologica 2011;96:1728-32.
61. Kawedia JD, Kaste SC, Pei D, Panetta JC, Cai X, Cheng C, et al. Pharmacokinetic, pharmacodynamic, and pharmacogenetic determinants of osteonecrosis in children with acute lymphoblastic leukemia. Blood 2011;117:2340-7.
62. Harrill AH, Desmet KD, Wolf KK, Bridges AS, Eaddy JS, Kurtz CL, et al. A mouse diversity panel approach reveals the potential for clinical kidney injury due to DB289 not predicted by classical rodent models. Toxicol Sci 2012;130:416-26.
63. Watters JW, Kraja A, Meucci MA, Province MA, McLeod HL. Genomewide discovery of loci influencing chemotherapy cytotoxicity. Proc Natl Acad Sci U S A 2004;101:11809-14.